Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Wednesday, July 19, 2017 2:04:18 PM
BY SHOSHANNA SOLOMON July 18, 2017, 5:55 pm
http://www.timesofisrael.com/biondvax-to-set-up-new-jerusalem-manufacturing-plant/
BiondVax Pharmaceuticals Ltd., a developer of a universal flu vaccine candidate, said Tuesday it will soon start construction of a new manufacturing facility in Jerusalem.
The Ness Ziona-based company whose shares are traded on the Nasdaq and in Tel Aviv said it has signed an agreement to lease a space of approximately 1,800 square meters in the Jerusalem BioPark, located in the Ein Kerem Hadassah campus, next to Hadassah University Hospitals and Hebrew University’s Medical School.
The mid-sized facility is expected to have the capacity to annually produce tens of millions of doses of the M-001 universal flu vaccine candidate, either in single-dose syringe or in bulk. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains.
“We expect our new facility will optimize production timelines and significantly reduce production costs,” said Dr Shimon Hassin, BiondVax’s Chief Operating Officer. “This new planned mid-size commercial manufacturing facility will mark the culmination of BiondVax’s transformation into a fully integrated pharmaceutical company,” operating under international standards.
Planning and design of the facility has begun, “while construction will begin soon,” the statement said.
Costs of building and operating the facility are partially supported by a previously announced grant from Israel’s Ministry of Economy and Industry and a €20 million agreement with the European Investment Bank, the statement said.
BiondVax said in June that €20 million loan from the European Investment Bank would help it take a step forward in bringing the vaccine onto the market. “We now have the resources to launch Phase 3 trials and set up a mid-sized commercial manufacturing plant,” Dr. Ron Babecoff, CEO of BiondVax said at the time.
BiondVax, established in 2005, licensed the technology from the Weizmann Institute, where it was developed in the mid-90s.
Recent BVXV News
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 04/30/2024 08:06:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2024 09:27:06 PM
- Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/12/2024 08:17:13 PM
- Scinai leadership to attend BIO-Europe Spring 2024 • PR Newswire (US) • 03/12/2024 12:00:00 PM
- Scinai Welcomes Liat Halpert as Head of Business Development and Sales • PR Newswire (US) • 02/13/2024 12:00:00 PM
- Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds • PR Newswire (US) • 01/04/2024 09:01:00 PM
- Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule • PR Newswire (US) • 11/20/2023 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM